I'm not sure they would want a significantly higher SP at the moment. There are $14M unlisted options at the end of August at 0.007. Any move above 0.007 will be met with these holders arbitraging their position (sell 0.008, buy back via options at 0.007).
now, with the drug translating to humans and 201 structured to be more efficacious than 202 (earlier MSA), why waste all this option SOI on 0.007 exercised options?. Hold off until just before readout and raise at 0.012. more money, less dilution.
just my musings.
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-78
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
-0.001(14.3%) |
Mkt cap ! $31.47M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.5¢ | $648.3K | 128.1M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4901441 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 22097257 | 20 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |